Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sangui Biotech Intl Inc (SGBI)

Sangui Biotech Intl Inc (SGBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sangui Biotech Intl Inc

Description:

Sangui BioTech International Inc began operations in October 1996. In August 1997, a publicly held company, Citadel Investment System, Inc., a Colorado corporation (Citadel), acquired one hundred percent of the outstanding common shares of Sangui BioTech, Inc., and as a result, Sangui BioTech, Inc. became a wholly owned subsidiary of Citadel. Thereafter, Citadel changed its name to Sangui BioTech International, Inc. (the Company or SGBI). The Company's mission is the development of novel and proprietary pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, Sangui GmbH. The Company's focus has been the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. SanguiBio GmbH holds the exclusive distribution rights for Chitoskin wound pads for the European Union and various other countries. The Company develops several products based on polymers of purified natural porcine hemoglobin with oxygen carrying abilities that are similar to those of native hemoglobin. These are oxygen carrying blood additives, and oxygen carrying blood volume substitutes. It is subject to governmental regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, and other similar laws of general application.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K
Short Volume Ratio 1.00

Growth:

1-Year Return -62.50%
3-Year Return -94.23%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%

SGBI Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 12.64
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar